News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Unprecedented Progression-Free Survival Benefit With Afatinib* Associated With Clinically Meaningful Improvements in Life-Limiting Lung Cancer Symptoms and Better Quality of Life


9/28/2012 10:19:00 AM

VIENNA--(BUSINESS WIRE)-- Data from LUX-Lung 3, the largest and most robust registration trial to datea in patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC) shows that the novel compound afatinib*, an irreversible ErbB Family Blocker, leads to better and longer control and improvement of the most common lung cancer-related symptoms and better quality of life (QoL) compared to chemotherapy (pemetrexed and cisplatin), considered best-in-class for non-squamous NSCLC.1,2 These findings further reinforce the outstanding first-line efficacy of afatinib* in patients with EGFR mutation positive NSCLC.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES